Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 6/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 2/20 | 0.35 |
| ▸ | VCP | P55072 | 1/20 | 0.35 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20655543 | 0.83 | GRM2 (0.42) | HTR2CHTR6PPARGHTR1BGRM2 | |
| SCHEMBL19089433 | 0.79 | HTR6 (0.40) | HTR2CHTR6VCPPOLBL3MBTL1 | |
| SCHEMBL4324839 | 0.78 | ROCK1 (0.50) | HTR2CHTR6L3MBTL1BRD4 | |
| SCHEMBL18574221 | 0.73 | HTR1B (0.47) | HTR1BNR2E1 | |
| SCHEMBL25068973 | 0.71 | TACR1 (0.39) | HTR2CHTR6PPARG | |
| SCHEMBL20655546 | 0.71 | KDM4E (0.44) | POLBBRD4 | |
| SCHEMBL13090965 | 0.69 | HTR2C (0.53) | HTR2CEZH2 | |
| SCHEMBL24481597 | 0.69 | EZH2 (0.37) | HTR2CEZH2 | |
| SCHEMBL18561728 | 0.69 | SMN1; SMN2 (0.48) | HTR1BL3MBTL1 | |
| SCHEMBL19910560 | 0.68 | EZH2 (0.40) | HTR2CHTR6EZH2HTR1BPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-07-09 | — | — | US | disclosed |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342796-B2 | Acrylanilide derivative, preparation method, and applications thereof in pharmacy | EGFR, ABL1, CSNK1A1 | HTR2C 2503/4885MPO 2495/4885HTR6 2326/4885 |
| US-20190015413-A1 | ACRYLANILIDE DERIVATIVE, PREPARATION METHOD, AND APPLICATIONS THEREOF IN PHARMACY | EGFR, ABL1, CSNK1A1 | HTR2C 2503/4885MPO 2495/4885HTR6 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.